Galderma Group Ag (GDERF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

warm welcome to Goderma's 25 first water trading update call. As customary, the press release was published at 7 a.m. Central European Standard Time today and can be consulted on our corporate website at any time. Today's presentation slides, as well as recording of the webcast, will be made available on our website after the call. Please be advised that today's presentation contains forward-looking statements which should be treated with the appropriate level of caution as advised on this slide. Let me now introduce today's trading update webcast. Dr. Flemming Onskov, CEO of Golderma, will provide a performance update for the first quarter, including key highlights by product category. Thomas Dittrich, CFO, will then introduce the trading update and the financial outlook for the year. Both Flemming and Thomas will be available to answer questions from the financial analysts before Flemming provides his final remarks to close the webcast. With this, I would like to invite Flemming to start the Golderma highlights for the first quarter of 2025. Flemming, over to you. Thank you, Emil. Good morning, good afternoon, and welcome to Golderma's first quarter 2025 trading update webcast. We are proud to report record performance ahead of expectations and a strong start to what we expect to be a year of opportunity for Golderma. There are five key opportunity areas for Galderma in 2025. This is the first of two years with significant launches. This includes the introduction of our two biologics with blockbuster potential, Nimluvio and Ralphides, along with Sculptra in China and also in South Korea later this year, Restylane Shape in Brazil, and continued innovation in dermatological skincare. For 2026, we have further launches planned along the same trajectory. We'll also con...